secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001104659-25-090113
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen licenses OCU400 gene therapy to Kwangdong for South Korea; $1M upfront, up to $6.5M milestones
--------------------------------------------------------------------------------

- Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.
- $1M upfront; up to $6.5M in regulatory/development milestones plus sales milestones of $1.5M per $15M sales.
- Royalty of 25% on net sales; Ocugen to manufacture commercial supply under separate agreement.
- Term continues until 20 years after first commercial sale or last valid patent/exclusivity expiry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/0001104659-25-090113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/tm2526167d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-090113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer